Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 485

1.

Managing dyslipidemia in chronic kidney disease.

Harper CR, Jacobson TA.

J Am Coll Cardiol. 2008 Jun 24;51(25):2375-84. doi: 10.1016/j.jacc.2008.03.025. Review.

2.

Statins for treatment of dyslipidemia in chronic kidney disease.

Shurraw S, Tonelli M.

Perit Dial Int. 2006 Sep-Oct;26(5):523-39. Review.

3.

The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.

Pennell P, Leclercq B, Delahunty MI, Walters BA.

Clin Nephrol. 2006 Nov;66(5):336-47.

PMID:
17140163
4.

[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].

Karie S, Launay-Vacher V, Deray G, Isnard-Bagnis C.

Presse Med. 2006 Feb;35(2 Pt 1):219-29. Review. French.

PMID:
16493350
5.

[Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].

Cases Amenós A, Goicoechea Diezhandiño M, de Alvaro Moreno F.

Nefrologia. 2008;28 Suppl 3:39-48. Spanish.

6.

Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.

Karas RH, Kashyap ML, Knopp RH, Keller LH, Bajorunas DR, Davidson MH.

Am J Cardiovasc Drugs. 2008;8(2):69-81.

PMID:
18422390
7.

[Treatment of dyslipidemia: how and when to combine lipid lowering drugs].

Schulz I.

Arq Bras Endocrinol Metabol. 2006 Apr;50(2):344-59. Epub 2006 May 23. Review. Portuguese.

8.

Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.

Fazio S.

Clin Ther. 2008 Feb;30(2):294-306. doi: 10.1016/j.clinthera.2008.02.004. Review.

PMID:
18343268
9.

Dyslipidemia and the progression of renal disease in chronic renal failure patients.

Cases A, Coll E.

Kidney Int Suppl. 2005 Dec;(99):S87-93. Review.

PMID:
16336584
10.

Lipid management in the geriatric patient.

Nair AP, Darrow B.

Endocrinol Metab Clin North Am. 2009 Mar;38(1):185-206. doi: 10.1016/j.ecl.2008.11.003. Review.

PMID:
19217519
11.

Management of dyslipidemias in patients with diabetes and chronic kidney disease.

Molitch ME.

Clin J Am Soc Nephrol. 2006 Sep;1(5):1090-9. Epub 2006 Jul 26. Review.

12.

Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.

Ahmed MH, Khalil AA.

Saudi J Kidney Dis Transpl. 2010 Nov;21(6):1021-9. Review.

13.

Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy.

Athyros VG, Mitsiou EK, Tziomalos K, Karagiannis A, Mikhailidis DP.

Expert Opin Pharmacother. 2010 Apr;11(5):723-30. doi: 10.1517/14656560903575654. Review.

PMID:
20210681
14.

Chronic kidney disease and statins: improving cardiovascular outcomes.

Walker DB, Walker TJ, Jacobson TA.

Curr Atheroscler Rep. 2009 Jul;11(4):301-8. Review.

PMID:
19500494
15.

Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence.

Kanbay M, Turgut F, Covic A, Goldsmith D.

J Nephrol. 2009 Sep-Oct;22(5):598-609. Review.

PMID:
19809992
16.

Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol.

Chrysant SG, Ibrahim M.

J Clin Hypertens (Greenwich). 2006 Jul;8(7):493-9; quiz 500-1. Review.

17.

Diabetic dyslipidemia: a practical guide to therapy.

Tovar JM, Bazaldua OV, Loffredo A.

J Fam Pract. 2008 Jun;57(6):377-88.

PMID:
18544321
18.

Fibrates in combination with statins in the management of dyslipidemia.

Jacobson TA, Zimmerman FH.

J Clin Hypertens (Greenwich). 2006 Jan;8(1):35-41; quiz 42-3. Review.

19.

The treatment of dyslipidemia--what's left in the pipeline?

Rau O, Zettl H, Popescu L, Steinhilber D, Schubert-Zsilavecz M.

ChemMedChem. 2008 Feb;3(2):206-21. Review.

PMID:
17963209
20.

Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.

Ascaso J, Gonzalez Santos P, Hernandez Mijares A, Mangas Rojas A, Masana L, Millan J, Pallardo LF, Pedro-Botet J, Perez Jimenez F, Pintó X, Plaza I, Rubiés J, Zúñiga M.

Am J Cardiovasc Drugs. 2007;7(1):39-58. Review. Erratum in: Am J Cardiovasc Drugs. 2007;7(4):302.

PMID:
17355165
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk